Ivonescimab for advanced clear cell kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug, ivonescimab, for people with advanced clear cell kidney cancer that has grown after at least one prior treatment. It may help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced clear cell kidney cancer that has spread.
- You have had at least one prior treatment for advanced disease, including a drug like Keytruda or Opdivo that targets PD-1/PD-L1.
- Your cancer has gotten worse after your last treatment.
- You have at least one tumor that can be measured on scans.
- You are able to perform daily activities with little or no help (ECOG 0-2).
- You are 18 years or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called ivonescimab for people with advanced adrenal gland tumors (adrenocortical carcinoma or pheochromocytoma/paraganglioma) that cannot be removed with surgery. The goal is to see if the drug can reduce or stop the growth of the tumors.
This trial tests a new drug called ivonescimab, which is a bispecific antibody that targets both PD-1 and VEGF. It is for people with metastatic colorectal cancer who have already tried standard treatments and may or may not have received immunotherapy before, depending on their tumor type.
This study tests a new immunotherapy medicine, ivonescimab, in people with advanced skin cancer or advanced prostate cancer. It looks at how safe and effective the drug is.
This trial tests a new oral drug (HC-7366) combined with two immunotherapy drugs (nivolumab and ipilimumab) for people with advanced clear cell kidney cancer. The goal is to see if adding this new drug can help shrink tumors or slow the cancer's growth.
This trial tests giving the drug ivonescimab before surgery for patients with high-risk clear cell kidney cancer. The goal is to see if it can help shrink the tumor and improve outcomes.
This study tests a new drug called ivonescimab for people with advanced endometrial or cervical cancer that has progressed after standard platinum-based chemotherapy. Ivonescimab is an investigational immunotherapy that may help your immune system fight the cancer.
Hear when a new Ivonescimab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.